entertainment -WSS

entertainment

author：entertainment 2025-09-29 12:09:01 - browse：91

Alnylam headquarters — Kristoffer Tripplaar/Sipa USA/AP

Alnylam Pharmaceuticals said Thursday that sales of its treatments for rare diseases grew 43% in the second quarter compared to the year-ago period, as the biotech prepares for a key meeting with the Food and Drug Administration in September.

Net product sales in the quarter were $306 million, led by Amvuttra, the company’s RNAi treatment for hereditary ATTR, with sales of $132 million, exceeding Wall Street forecasts. Sales of Onpattro, its older medicine for hereditary ATTR, were $91 million, slightly less than expectations.

The FDA has scheduled a meeting of outside experts on Sept. 13 to discuss the company’s application to expand the indication for Onpattro to include ATTR-CM, a related condition that affects the heart. The FDA decision is due by Oct. 8. An expansion would open a much larger market for the drug than its current approval, which largely targets nerve-related damage.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Hollywood unions extend contract negotiations for actors
Next article： FDA rejects Alnylam's heart disease treatment over insufficient data

WSS

In $4.8 billion deal, Bristol Myers Squibb to buy cancer player Mirati

FDA authorizes Novavax’s updated Covid

Liquid biopsy for lung cancer is launched by Delfi

Why Charlie Gard's case is so disturbing to Americans

A new approach to psychiatric drug development

Readout Newsletter: BridgeBio, Akero, and human embryo models

explore

entertainment

knowledge

United colonoscopy coverage change 'may cost lives,' doctors say

Bill would stop addiction treatment from triggering child abuse inquiry

In Memoriam: Notable people who died in 2023

Senate panel eyes new effort on drug shortages

Anesthesiologist group: stop taking Ozempic before surgery

AI can decode, harness the power of the humane immune system

Hollywood unions extend contract negotiations for actors

Was Amgen transparent enough on FDA's concern on cancer drug?

New air purifier tech could be key to improving indoor air quality

Chan Zuckerberg Biohub Chicago to focus on inflammation

Wikipedia

Liquid biopsy for lung cancer is launched by Delfi

Chan Zuckerberg Biohub Chicago to focus on inflammation

Immune cells and nerve overgrowth may explain recurring UTI pain

Harvard's David Sinclair gets blowback over aging

For AI in health care standards, federal regulators join with industry group

FDA authorizes Novavax’s updated Covid

hotspot

explore

knowledge

Wikipedia